Cook, AcuityBio ink deal for lung cancer drug technology

Cook Biotech will collaborate with drug-delivery maker AcuityBio on Acuity’s lead lung cancer product, the companies said today.

Acuity’s ABC103 will use Cook Biotech’s proprietary extracellular matrix (ECM) technology. ABC103 is a platform technology designed for localized, sustained drug delivery to prevent post-surgical lung cancer recurrence. It combines approved/ cleared surgical staple-line buttress, drug-eluting polymers and a chemotherapeutic drug, paclitaxel.

The FDA has granted ABC103 orphan drug designation for this indication. Phase I clinical testing of is scheduled to begin in late 2019. Acuity is developing other applications for the ABC drug-delivery platform.

Get the full story on our sister site, Drug Delivery Business.

The post Cook, AcuityBio ink deal for lung cancer drug technology appeared first on MassDevice.

from MassDevice https://ift.tt/2NnYB7d